These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 8237075)
41. Renal and vascular protective effects of cilnidipine in patients with essential hypertension. Morimoto S; Yano Y; Maki K; Iwasaka T J Hypertens; 2007 Oct; 25(10):2178-83. PubMed ID: 17885563 [TBL] [Abstract][Full Text] [Related]
42. Mibefradil, a pharmacologically distinct calcium antagonist. Ernst ME; Kelly MW Pharmacotherapy; 1998; 18(3):463-85. PubMed ID: 9620098 [TBL] [Abstract][Full Text] [Related]
43. [Role of calcium antagonists in the treatment of atherosclerosis]. Aron A; Aron L Harefuah; 1993 Aug; 125(3-4):90-3. PubMed ID: 8225086 [No Abstract] [Full Text] [Related]
44. [Action of intrinsic low density lipoprotein in the vascular wall. Significance for the pathogenesis of essential hypertension and arteriosclerosis]. Sachinidis A; Ko Y; Vetter W; Vetter H Med Klin (Munich); 1994 Dec; 89(12):662-7. PubMed ID: 7870001 [No Abstract] [Full Text] [Related]
46. [The role of new dihydropyridine calcium channel blockers in the treatment of hypertension]. Coca A An Med Interna; 2003 Jun; 20(6):279-81. PubMed ID: 12848596 [No Abstract] [Full Text] [Related]
47. Protective action of calcium channel antagonists in atherogenesis and experimental vascular injury. Weinstein DB; Heider JG Am J Hypertens; 1989 Mar; 2(3 Pt 1):205-12. PubMed ID: 2645920 [TBL] [Abstract][Full Text] [Related]
49. The voltage-dependent non-selective cation channel sensitive to the L-type calcium channel blocker efonidipine regulates Ca2+ influx in brain vascular smooth muscle cells. Matsuoka T; Nishizaki T; Nomura T Biochem Biophys Res Commun; 1997 Nov; 240(2):484-7. PubMed ID: 9388505 [TBL] [Abstract][Full Text] [Related]
50. Hypertension treatment and prevention of new atherosclerotic plaque formation. Rafflenbeul W Drugs; 1994; 48 Suppl 1():11-5. PubMed ID: 7533701 [TBL] [Abstract][Full Text] [Related]
51. [ELSA Studies studies progression of atherosclerosis. Calcium antagonist arrests the process more than a beta-blocker]. Einecke D MMW Fortschr Med; 2001 Jul; 143(26-27):6. PubMed ID: 11481923 [No Abstract] [Full Text] [Related]
53. Update on calcium antagonists. Delafontaine P Heart Dis Stroke; 1992; 1(6):366-71. PubMed ID: 1344133 [No Abstract] [Full Text] [Related]
54. [Molecular effects of new calcium antagonists: is the principle of parcimony out of place?]. Richard S; Virsolvy A; Fort A Ann Cardiol Angeiol (Paris); 2008 Jun; 57(3):166-73. PubMed ID: 18565491 [TBL] [Abstract][Full Text] [Related]
55. [Determination of 45Ca transmembrane flux and its application to research on calcium antagonists]. Dong H; Yang ZC Sheng Li Ke Xue Jin Zhan; 1990 Apr; 21(2):171-4. PubMed ID: 2169645 [No Abstract] [Full Text] [Related]
56. Calcium channel antagonists. What do the second-generation agents have to offer? Salerno SM; Zugibe FT Postgrad Med; 1994 Jan; 95(1):181-90. PubMed ID: 8278298 [TBL] [Abstract][Full Text] [Related]